What is the half-life of P21 (Cerebrolysin-derived)?

P21 (Cerebrolysin-derived) has a half-life of ~2-4 hours (estimated from animal studies), which is why it's typically administered once daily for optimal therapeutic effect.

How do I reconstitute P21 (Cerebrolysin-derived)?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Healing & Recovery

Preclinical

P21 (Cerebrolysin-derived)

Also known as: P021, P21 peptide, Cerebrolysin-derived P21

Overview

Key Facts

Primary Goal: A small synthetic peptide derived from the active region of ciliary neurotrophic factor (CNTF), identified through research aimed at creating a drug-like compound that replicates key neurotrophic effects of Cerebrolysin

A small synthetic peptide derived from the active region of ciliary neurotrophic factor (CNTF), identified through research aimed at creating a drug-like compound that replicates key neurotrophic effects of Cerebrolysin. P21 crosses the blood-brain barrier and promotes neurogenesis and synaptic plasticity without the mitogenic activity associated with full-length neurotrophic factors. Half-Life ~2-4 hours (estimated from animal studies) Typical Dose 500–1500 mcg Frequency once daily Cycle Length 4-12 weeks

Dosing Information

Half-Life

~2-4 hours (estimated from animal studies)

Typical Dose

500–1500 mcg

Frequency

once daily

Cycle Length

4-12 weeks

Administration Routes:

subcutaneous

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Research Summary

Preclinical

P21 was developed by Dr. Khalid Iqbal and colleagues at the New York State Institute for Basic Research in Developmental Disabilities. Published studies in Neurobiology of Aging (2011, 2013) demonstrated that P21 administration rescued cognitive deficits in Alzheimer's disease mouse models by promoting neurogenesis and reducing tau pathology. The peptide increased hippocampal neurogenesis by approximately 40-60% in aged mice and significantly improved performance in Morris water maze tests. It remains preclinical with no human trials completed.